Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34604
Abstract: Although the clinical outcomes of patients with TP53‐mutated acute myeloid leukemia (AML) are dismal, subsets of patients eligible for curative‐intent therapies may fare better. Because racial disparities are known to affect outcome in hematologic malignancies,… read more here.
Keywords: mutated acute; myeloid leukemia; patients tp53; acute myeloid ... See more keywords
Hedgehog signaling negatively co-regulates BH3-only protein Noxa and TAp73 in TP53-mutated cells.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer letters"
DOI: 10.1016/j.canlet.2018.04.025
Abstract: In the present study, we show that pharmacological repression by the Hedgehog (Hh) pathway inhibitor (HPI) GANT61 induces expression of the proapoptotic protein Noxa in TP53-mutated embryonal pediatric tumor cells driven by Hh signaling (i.e.… read more here.
Keywords: protein; protein noxa; tp53 mutated; noxa tap73 ... See more keywords
Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
Sign Up to like & getrecommendations! Published in 2022 at "Leukemia Research Reports"
DOI: 10.1016/j.lrr.2021.100286
Abstract: Myeloid sarcoma (MS) is a rare extramedullary blast proliferation of immature cells of myeloid origin. It is commonly associated with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasm (MPN), and may precede, coincide… read more here.
Keywords: tp53 mutated; myeloproliferative neoplasm; decitabine venetoclax; myeloid sarcoma ... See more keywords
What have we learned about TP53-mutated acute myeloid leukemia?
Sign Up to like & getrecommendations! Published in 2024 at "Blood Cancer Journal"
DOI: 10.1038/s41408-024-01186-5
Abstract: TP53 is a tumor suppressor gene frequently mutated in human cancers and is generally associated with poor outcomes. TP53 mutations are found in approximately 5% to 10% of patients with de novo acute myeloid leukemia… read more here.
Keywords: acute myeloid; tp53 mutated; myeloid leukemia;
Arsenic Trioxide exerts cytotoxic and radiosensitizing effects in pediatric Medulloblastoma cell lines of SHH Subgroup
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-63808-9
Abstract: We evaluated the potential effects of ATO in different pediatric SHH-MB cell lines (ONS-76: TP53 -wild type; DAOY and UW402: TP53 -mutated). MB cell lines molecular subgroup was confirmed and TP53 mutations were validated. Cell… read more here.
Keywords: subgroup; shh cell; tp53 mutated; cell lines ... See more keywords
Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes.
Sign Up to like & getrecommendations! Published in 2023 at "Hematology"
DOI: 10.1080/16078454.2023.2181773
Abstract: OBJECTIVE To explore the clinical outcomes and characteristics of TP53-mutated primary myelodysplastic syndromes (MDS). METHODS A total of 74 de novo primary MDS patients who were diagnosed and treated in the Department of Hematology of… read more here.
Keywords: clinical outcomes; group; hematology; tp53mut group ... See more keywords
Precision medicine for TP53-mutated acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Precision Medicine and Drug Development"
DOI: 10.1080/23808993.2019.1644164
Abstract: ABSTRACT Introduction: TP53 mutations in acute myeloid leukemia (AML) are associated with poor response to standard chemotherapy and high rates of relapse, even after allogeneic stem cell transplantation. The mutated p53 protein is likely to… read more here.
Keywords: medicine; tp53 mutated; myeloid leukemia; acute myeloid ... See more keywords
PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Genetics"
DOI: 10.1111/cge.14260
Abstract: Immune checkpoint inhibitors (ICIs) improve overall survival in patients with advanced gastric cancer (GC). However, the molecular characterization of GC in ICIs responders is unclear. A total of 288 advanced GC patients were included in… read more here.
Keywords: tp53; gastric cancer; somatic mutations; tp53 mutated ... See more keywords
Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Pathology"
DOI: 10.1136/jcp-2024-209954
Abstract: We investigated the prognostic impact of blast counts, TP53 allelic state determinants (number of hits, del(17p), variant allele frequency, complex karyotype),and a novel karyotypic clonal cell fraction (≤50% clonal cells vs >50% clonal cells (termed… read more here.
Keywords: fraction; tp53 mutated; outcome; myeloid neoplasms ... See more keywords
Abstract 3179: Spindle assembly checkpoint as a therapeutic target for TP53-mutated myeloid neoplasms
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-3179
Abstract: Introduction TP53-mutated (TP53mut) myeloid neoplasms (MN) are a distinct entity of myeloid neoplasms with no effective therapies and poor survival (Grob et al, Blood 2022). The TP53-deficient state facilitates the downstream dysfunction of the spindle… read more here.
Keywords: tp53 mutated; tp53mut; cell; myeloid neoplasms ... See more keywords
Abstract 4691: Concurrent EGFR inhibition and radiotherapy potentiates radioresistance in TP53-mutated endometrial cancer
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-4691
Abstract: Endometrial cancers (EC) that harbor TP53 mutations portend a worse clinical prognosis. EGFR inhibition has emerged as a potential radio-sensitizing strategy, particularly in NSCLC and HNSCC, however, its effect in TP53-mutated tumors is mixed. As… read more here.
Keywords: endometrial cancer; cancer; tp53 mutated; egfr inhibition ... See more keywords